The path from a cannabis plant to pharmaceuticals and treatment

An interview with Prof. Dedi Meiri

Share on linkedin
Share on facebook
Share on twitter

What are the recent advances in the field of clinical applications for cannabis and its compounds? How can you monitor cannabis derived compounds to create a combination that activates different receptors and stimulate complex reactions that lead to holistic treatment? How important is to have genetic control and stability of a cannabis plant for precise compound composition that may serve as medicine? How can the current limitations of using cannabis extract be resolved through plant genetics?

All these highly relevant questions and more are discussed and answered in the current podcast.

Dedi (David) Meiri, PhD, is an Associate Professor at the Faculty of Biology at the Technion and a member of the Technion Integrated Cancer Center (TICC). His lab investigates the therapeutic potential of cannabinoids, the naturally occurring chemicals found in the cannabis plant. Researchers work on a variety of projects in the lab with its main focus on how cannabinoids affect various types of cancer, epilepsy, Alzheimer, sleep disorders, multiple sclerosis and more.                                                                                                                                                      

A man on a mission, Prof. Meiri aims to understand the cannabis plant thoroughly enough so that a doctor can prescribe the right treatment at the right dosage for a particular patient. To that end, he collaborates with cannabis growers, clinicians, major manufacturers, and distributors of medical cannabis to identify almost every strain of marijuana grown in Israel, matching them to the diseases they affect. He has launched the Database Project, which exhaustively profiles compounds given to Israel’s 60,000 medical marijuana patients. Prof. Meiri also helps Israel’s Ministry of Health advance its understanding of cannabis usage.

Let’s get started!